ArticleScientific reports2025
The prevalence and predictors of non-alcoholic fatty liver disease in Chinese patients with inflammatory bowel disease: a multicenter retrospective study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rising Burden and Clinical Impact of Metabolic Syndrome in Inflammatory Bowel Disease: A Real-World Cohort Study.United European gastroenterology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has a higher prevalence in inflammatory bowel disease (IBD) patients compared to the general population. Herein, the prevalence and predictors of NAFLD in a large IBD cohort were evaluated by non-invasive method. A multicenter retrospective study was conducted among 592 inpatients diagnosed with IBD who underwent abdominal ultrasound. Characteristics of IBD and metabolic status were collected, presence of hepatic steatosis was assessed, and predictors for NAFLD were analyzed. A total of 509 IBD patients were included in the final analysis including 245 NAFLD (48.1%) subjects. IBD patients with NAFLD were older than those without NAFLD. NAFLD patients had more diabetes, higher body mass index (BMI) and more obesity. The patients with NAFLD showed increased levels of gamma-glutamyl transferase, uric acid, glycemia, triglycerides and low density lipoprotein. The localization of ulcerative colitis showed a more extensive trend in NAFLD patients compared with non-NAFLD subjects. Multivariate analysis showed that NAFLD was independently associated with BMI levels, biologic agents using, and prior surgery in IBD patients. NAFLD is common in Chinese patients with IBD. Obesity and biologics using are risk factors, and prior intestinal surgery is a protective factor of NAFLD development. These findings should be interpreted in the context of an inpatient-based study population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.